search
Back to results

Dasatinib Plus Quercetin for Accelerated Aging in Mental Disorders

Primary Purpose

Schizophrenia, Treatment Resistant Depression, Aging, Premature

Status
Recruiting
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Dasatinib + quercetin
Sponsored by
Washington University School of Medicine
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Schizophrenia focused on measuring Schizophrenia, Treatment Resistant Depression, Aging, Premature, Older Adults

Eligibility Criteria

50 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Either major depression, which is treatment-resistant (currently depressed despite at least 2 adequate trials of antidepressants in this or the previous episode), or schizophrenia/schizoaffective disorder. Age 50+ (60+ for depression). Three conditions associated with aging (e.g., hypertension/diabetes/metabolic syndrome, cardiac disease, lung disease other than asthma, cancer with adult-onset, arthritis, and inflammatory diseases typically seen in aging). No history of dementia by patient report. Already taking an adequate dose of medication for schizophrenia/schizoaffective disorder or depression. Exclusion Criteria: Contraindications for dasatinib or quercetin Active SI such that participant could not be safely managed in an outpatient clinical trial. Taking medications that are strong CPY3A4 inhibitors or strong inducers, or that induce senescence (e.g., alkylating agents, anthracyclines, platins/other chemotherapy), or everolimus and topotecan (which have interactions with quercetin). All medications and medical conditions will be reviewed by physician study investigators to determine whether the medication or condition, in the opinion of the investigators, makes the participant inappropriate for the study. Examples of such potential excluding conditions: Active inflammatory, infectious, or malignant disease; sensory deficits that would interfere with assessments; recent heart attack or stroke; severe bleeding disorder; uncontrolled hypertension or diabetes mellitus; active liver disease or cirrhosis; current use of systemic steroids, quinolone antibiotics, hydroxychloroquine or chloroquine.

Sites / Locations

  • Washington University School of MedicineRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Dasatinib + quercetin

Arm Description

open label dasatinib plus quercetin combined as a drug therapy

Outcomes

Primary Outcome Measures

Number of participants who successfully completed and safely tolerated the intervention
Test the safety and feasibility of dasatinib plus quercetin

Secondary Outcome Measures

Full Information

First Posted
April 17, 2023
Last Updated
August 31, 2023
Sponsor
Washington University School of Medicine
Collaborators
UConn Health
search

1. Study Identification

Unique Protocol Identification Number
NCT05838560
Brief Title
Dasatinib Plus Quercetin for Accelerated Aging in Mental Disorders
Official Title
Dasatinib Plus Quercetin for Accelerated Aging in Mental Disorders
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
July 1, 2023 (Actual)
Primary Completion Date
May 1, 2025 (Anticipated)
Study Completion Date
May 1, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Washington University School of Medicine
Collaborators
UConn Health

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This pilot open-label study examines the effects of a combination of dasatinib plus quercetin - two drugs that have known senolytics properties - on physiological aging in older individuals with depression or schizophrenia.
Detailed Description
This is a pilot study that will enroll up to 40 participants and will examine the following: test the safety and feasibility of dasatinib+quercetin in two mental illnesses associated with accelerated aging: schizophrenia and treatment-resistant depression examine changes in SASP (senescence-associated secretory phenotype) with dasatinib+quercetin treatment examine acute and long-term changes in neuropsychological functioning, functional status, and brain markers of aging, as well as in clinical symptoms of the illnesses (treatment-resistant depression and schizophrenia). This study will also combine the treatment of dasatinib plus quercetin and lifestyle-based risk factor management - which will involve the research team during the medication intervention portion to provide lifestyle education focusing on strength, balance, and nutrition. The research team will maintain close contact with participants to offer encouragement, address questions and help navigate barriers to engaging in the activities. Before study enrollment, participants will be screened using questionnaires and a phone screen prior to being consented. The participant will be involved for about 1 year and self-administer 8 total doses of the medications - two consecutive days of dasatinib 100mg orally plus quercetin 1250mg orally on weeks 1 (ie., 2 days on, 5 days off), 2, 3, and 4. The participant will undergo an MRI scan at baseline and approximately week 10 of the study. Blood draws will occur at baseline, week 1, 2, 3, 4, 10, and at the endpoint. 10 ml of blood will be taken each time for 700 ml over 1 year. Participants will have several questionnaires and assessments to complete at baseline, week 10, and the study's endpoint.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Schizophrenia, Treatment Resistant Depression, Aging, Premature
Keywords
Schizophrenia, Treatment Resistant Depression, Aging, Premature, Older Adults

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Model Description
Open-label
Masking
None (Open Label)
Allocation
N/A
Enrollment
40 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Dasatinib + quercetin
Arm Type
Experimental
Arm Description
open label dasatinib plus quercetin combined as a drug therapy
Intervention Type
Drug
Intervention Name(s)
Dasatinib + quercetin
Intervention Description
dasatinib 100mg / quercetin 1250mg The intervention will involve the participant taking both dasatinib and quercetin combined.
Primary Outcome Measure Information:
Title
Number of participants who successfully completed and safely tolerated the intervention
Description
Test the safety and feasibility of dasatinib plus quercetin
Time Frame
10 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Either major depression, which is treatment-resistant (currently depressed despite at least 2 adequate trials of antidepressants in this or the previous episode), or schizophrenia/schizoaffective disorder. Age 50+ (60+ for depression). Three conditions associated with aging (e.g., hypertension/diabetes/metabolic syndrome, cardiac disease, lung disease other than asthma, cancer with adult-onset, arthritis, and inflammatory diseases typically seen in aging). No history of dementia by patient report. Already taking an adequate dose of medication for schizophrenia/schizoaffective disorder or depression. Exclusion Criteria: Contraindications for dasatinib or quercetin Active SI such that participant could not be safely managed in an outpatient clinical trial. Taking medications that are strong CPY3A4 inhibitors or strong inducers, or that induce senescence (e.g., alkylating agents, anthracyclines, platins/other chemotherapy), or everolimus and topotecan (which have interactions with quercetin). All medications and medical conditions will be reviewed by physician study investigators to determine whether the medication or condition, in the opinion of the investigators, makes the participant inappropriate for the study. Examples of such potential excluding conditions: Active inflammatory, infectious, or malignant disease; sensory deficits that would interfere with assessments; recent heart attack or stroke; severe bleeding disorder; uncontrolled hypertension or diabetes mellitus; active liver disease or cirrhosis; current use of systemic steroids, quinolone antibiotics, hydroxychloroquine or chloroquine.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Marissa Rhea
Phone
314-362-3797
Email
marissa@wustl.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Julia Schweiger
Phone
314-362-3153
Email
schweigj@wustl.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Eric Lenze, MD
Organizational Affiliation
Washington University School of Medicine, Department of Psychiatry
Official's Role
Principal Investigator
Facility Information:
Facility Name
Washington University School of Medicine
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Julie Schweiger
Phone
314-362-3153
Email
schweigj@psychiatry.wustl.edu
First Name & Middle Initial & Last Name & Degree
Eric Lenze, MD

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Deidentified data available upon request
IPD Sharing Time Frame
Data will be available by request within 1 year of the final data collection.
IPD Sharing Access Criteria
Contact study PI

Learn more about this trial

Dasatinib Plus Quercetin for Accelerated Aging in Mental Disorders

We'll reach out to this number within 24 hrs